ArticleFrontiers in microbiology2019
Pyoverdine-Dependent Virulence of
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 101 citations in OpenAlex.
- Article
- A functional screen for bacterial ubiquitin regulation identifies an unusual Pseudomonas aeruginosa E3 ligase.The EMBO journal · 2026Article
- Differential Metabolite Production Underlies Disruption of the Cystic Fibrosis Airway Microbiota by Pathogens.bioRxiv : the preprint server for biology · 2026Article
- R pyocin sensitivity ofJournal of medical microbiology · 2026Article
- Exploring the anti-quorum sensing potential of synthetic lipstick dyes againstNew microbes and new infections · 2026Article
- Article
- Loss of the ferripyochelin receptor FptA drives reduced cefiderocol susceptibility and impairs fitness inAntimicrobial agents and chemotherapy · 2026Article
- The Burden of Antimicrobial-Resistant Pseudomonas aeruginosa Isolates in Children With Cystic Fibrosis: Molecular Characterization and Genotyping Analysis.MicrobiologyOpen · 2026Article
- A Novel Quinolone JH62 (E-2-(Tridec-4-en-1-yl)-quinolin-4(1H)-one) fromMicroorganisms · 2025Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- Loss of the Ferripyochelin Receptor FptA Drives Reduced Cefiderocol Susceptibility and Impairs Fitness inbioRxiv : the preprint server for biology · 2025Article
- Effects of influenza A infection on liberation of bacteria from biofilms and inflammatory response in anMicrobiology (Reading, England) · 2025Article
- Dual-species proteomics and targeted intervention of animal-pathogen interactions.Journal of advanced research · 2025Article
- Bio-informed synthesis of marine-sourced indole derivatives: suppressing gram-negative bacteria biofilm and virulence.BMC biology · 2025Article
- Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung.PLoS pathogens · 2025Article
- Establishment and characterization of persistentInfection and immunity · 2025Article
- Green Biosynthesis of Bimetallic Copper Oxide-Selenium Nanoparticles Using Leaf Extract ofInternational journal of nanomedicine · 2025Article
- Host-mimicking conditions promoteFrontiers in microbiology · 2025Article
- EF-hand calcium sensor, EfhP, controls transcriptional regulation of iron uptake by calcium inmBio · 2024Article
- Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection.Communications biology · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The development of therapies that modulate or prevent pathogen virulence may be a key strategy for circumventing antimicrobial resistance. Toward that end, we examined the production of pyoverdine, a key virulence determinant, in ∼70
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.